Fingolimod | Interferon beta-1b | Intramuscular interferon beta-1a | Subcutaneous interferon beta-1a | Glatiramer acetate | |||||
---|---|---|---|---|---|---|---|---|---|
N=152 | N=35 | N=66 | N=98 | N=115 | |||||
p-value | p-value | p-value | p-value | ||||||
PDC: mean (SD) | 0.83 (0.23) | 0.61 (0.30) | 0.0002 | 0.67 (0.32) | 0.0004 | 0.68 (0.31) | 0.0001 | 0.73 (0.30) | 0.0040 |
PDC Categories (%) | |||||||||
0-<0.2 | 4.61 | 17.14 | 0.0009 | 9.09 | 0.0002 | 10.20 | 0.0002 | 6.09 | 0.0003 |
0.2-<0.4 | 3.95 | 8.57 | 22.73 | 11.22 | 11.30 | ||||
0.4-<0.6 | 2.63 | 11.43 | 4.55 | 12.24 | 13.91 | ||||
0.6-<0.8 | 15.13 | 22.86 | 10.61 | 18.37 | 7.83 | ||||
0.8-1 | 73.68 | 40.00 | 53.03 | 47.96 | 60.87 | ||||
MPR: mean (SD) | 0.92 (0.08) | 0.82 (0.18) | 0.0066 | 0.88 (0.13) | 0.0287 | 0.84 (0.19) | 0.0004 | 0.89 (0.16) | 0.0602 |
MPR Categories (%) | 0.0001 | 0.0069 | 0.0004 | 0.0106 | |||||
0-<0.2 | 0.00 | 0.00 | 0.00 | 1.10 | 0.93 | ||||
0.2-<0.4 | 0.00 | 3.33 | 0.00 | 3.30 | 1.85 | ||||
0.4-<0.6 | 0.00 | 10.00 | 5.00 | 5.49 | 5.56 | ||||
0.6-<0.8 | 9.52 | 16.67 | 16.67 | 18.68 | 6.48 | ||||
0.8-1 | 90.48 | 70.00 | 78.33 | 71.43 | 85.19 | ||||
Persistence (<60 day gap) (%) | 74.34 | 42.86 | 0.0003 | 53.03 | 0.0020 | 54.08 | 0.0009 | 62.61 | 0.0396 |
Persistent days (days till first 60-day gap) (%) | |||||||||
No gap | 74.34 | 42.86 | 53.03 | 54.08 | 62.61 | ||||
1-90 | 6.58 | 22.86 | 15.15 | 19.39 | 12.17 | ||||
91-180 | 4.61 | 5.71 | 21.21 | 10.20 | 13.91 | ||||
181-270 | 9.21 | 17.14 | 6.06 | 10.20 | 6.96 | ||||
270+ | 5.26 | 11.43 | 4.55 | 6.12 | 4.35 | ||||
Switched to other DMTs after discontinuation (%) | 4.61 | 11.43 | 0.1219 | 13.64 | 0.0188 | 9.18 | 0.1488 | 13.04 | 0.0130 |